Acesso livre
Acesso livre

Covid-19

Estudo de coorte | Taxas de incidência e desfechos clínicos da infecção por SARS-CoV-2 com as variantes Ômicron e Delta em crianças menores de 5 anos nos EUA.

8 Abr, 2022 | 17:27h

Incidence Rates and Clinical Outcomes of SARS-CoV-2 Infection With the Omicron and Delta Variants in Children Younger Than 5 Years in the US – JAMA Pediatrics

Comentário: Omicron ‘less severe’ than Delta for children ages 4 and younger, study suggests – Case Western Reserve University

 

Comentário no Twitter

 

Revisão e M-A | Reabilitação pulmonar pós-Covid.

8 Abr, 2022 | 17:18h

Estudo 1: The effectiveness of pulmonary rehabilitation for Post-COVID symptoms: A rapid review of the literature – Respiratory Medicine

Estudo 2: Effect of Pulmonary Rehabilitation for Patients With Post-COVID-19: A Systematic Review and Meta-Analysis – Frontiers in Medicine

Diretriz de consenso | Definição, diagnóstico e tratamento da mucormicose pulmonar associada a COVID-19.

6 Abr, 2022 | 12:57h

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India – The Lancet Infectious Diseases

Perspectiva | As evidências sobre a 4ª dose das vacinas contra Covid & a questão complicada dos limites de idade.

6 Abr, 2022 | 12:53h

The Evidence On 4th Doses of Covid Vaccines & the Thorny Question of Age Thresholds – Absolutely Maybe Blog, by Hilda Bastian

Conteúdos relacionados:

U.S. approves second Covid-19 booster for people 50 and older and immunocompromised individuals.

[Preprint] Retrospective cohort study: second booster vaccine and Covid-19 mortality in adults 60 to 100 years old.

Among health care workers, a fourth dose vaccine effectiveness against any SARS-CoV-2 Omicron variant infection was 30% for the Pfizer–BioNTech and 11% for the Moderna.

[Preprint] Fourth dose of COVID vaccine offers only slight boost against Omicron infection.

Covid-19: Fourth vaccine doses—who needs them and why?

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

 

Comentário no Twitter

 

Estudo randomizado | Eficácia, segurança e imunogenicidade da vacina de DNA contra SARS-CoV-2 (ZyCoV-D).

6 Abr, 2022 | 12:48h

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India – The Lancet

Comentário convidado: DNA vaccines join the fight against COVID-19 – The Lancet

 

Comentário no Twitter

 

Estudo de coorte | Mudança nas taxas de mortalidade por doença cardíaca e AVC antes e durante a pandemia de Covid-19.

6 Abr, 2022 | 12:46h

Age-Adjusted Mortality Rates and Age and Risk–Associated Contributions to Change in Heart Disease and Stroke Mortality, 2011-2019 and 2019-2020 – JAMA Network Open

Comentários:

Several-Fold Increase in Stroke and Heart Disease Deaths During COVID-19 Pandemic – NeurologyToday

2019 to 2020 Saw Risk-Linked Deaths From Heart Disease, Stroke Up – HealthDay

 

Comentário do autor no Twitter (fio – clique pra saber mais). Artigo e imagens sob CC-BY License

 

Estratégia da OMS para preparo, prontidão e plano de resposta para o fim da emergência global de Covid-19 em 2022.

5 Abr, 2022 | 12:30h

Strategic Preparedness, Readiness and Response Plan to End the Global COVID-19 Emergency in 2022 – World Health Organization

 

Comentário no Twitter (fio – clique para saber mais)

 

Segurança, tolerabilidade e cinética viral durante o desafio do SARS-CoV-2 humano em adultos jovens (infectando indivíduos deliberadamente em ambiente controlado).

5 Abr, 2022 | 12:20h

Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults – Nature Medicine

Comentários:

Understanding COVID-19 through human challenge models – Nature Medicine

First human challenge study of Covid-19 yields valuable insights about how we get sick – CNN

First Human Challenge Trial Shows How COVID-19 Strikes – HealthDay

Conteúdos relacionados:

Scientists deliberately gave people COVID — here’s what they learnt.

[Preprint] Results from the first Covid-19 human challenge study (deliberately infecting individuals in a controlled environment).

Perspective | SARS-CoV-2 human challenge studies — establishing the model during an evolving pandemic.

World’s first coronavirus “Human Challenge” study receives ethics approval in the UK  (vários textos sobre o assunto)

Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

 

Comentário no Twitter

 

Dois novos estudos mostram que a vacinação forneceu proteção adicional após infecção por Covid-19.

5 Abr, 2022 | 12:14h

Estudo 1: Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden – The Lancet Infectious Diseases

Estudo 2: Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study – The Lancet Infectious Diseases

Comentários:

Interplay of infection and vaccination in long-term protection from COVID-19 – The Lancet Infectious Diseases

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world – The Lancet Infectious Diseases

Vaccines offer substantial extra protection after COVID-19 infection – CIDRAP

Had COVID? Getting Vaccine Boosts Resilience Even More, Studies Show – HealthDay

Conteúdos relacionados:

Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.

Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.

 

Comentário no Twitter fio – clique para saber)

 

Estudo mostra que a transmissão mãe-filho da infecção por COVID-19 é possível, porém rara.

1 Abr, 2022 | 13:12h

Comunicado de imprensa: Mother to child transmission of COVID-19 infection, possible but rare, study finds – University of Birmingham

Estudo original: SARS-CoV-2 positivity in offspring and timing of mother-to-child transmission: living systematic review and meta-analysis – The BMJ

Editorial: Transmission of SARS-CoV-2 from mother to baby is rare

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.